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Abstract
Background: Human parvovirus B19 (B19V), cytomegalovirus (CMV) and Toxoplasma gondii (T. gondii) may cause
intrauterine infections with potentially severe consequences to the fetus. Current serodiagnosis of these infections is
based on detection of antibodies most often by EIA and individually for each pathogen. We developed singleplex
and multiplex microsphere-based Suspension Immuno Assays (SIAs) for the simultaneous detection of IgG
antibodies against B19V, CMV and T. gondii.
Methods: We tested the performances of SIAs as compared to in-house and commercial reference assays using
serum samples from well-characterized cohorts.
Results: The IgG SIAs for CMV and T. gondii showed good concordance with the corresponding Vidas serodiagnostics.
The B19V IgG SIA detected IgG in all samples collected >10 days after onset of symptoms and showed high
concordance with EIAs (in-house and Biotrin). The serodiagnostics for these three pathogens performed well in
multiplex format.
Conclusions: We developed singleplex and multiplex IgG SIAs for the detection of anti-B19V,-CMV and -T. gondii
antibodies. The SIAs were highly sensitive and specific, and had a wide dynamic range. These components thus
should be suitable for construction of a multiplex test for antibody screening during pregnancy.
Keywords: Microsphere-based suspension immuno assay, Singleplex and multiplex, B19V, CMV, T. gondii,
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Background
Human parvovirus B19 (B19V), cytomegalovirus (CMV)
and Toxoplasma gondii (T. gondii) are ubiquitous patho-
gens causing diverse clinical manifestations. Their pri-
mary infections during pregnancy may lead to severe
sequelae. Thus, the serological status of the mother is
critically important in counselling and recognition of
acute infection [1–3].
The current standards in antibody detection are
enzyme-immuno assay (EIA) and chemiluminescence
immune assay (CLIA) performed individually for each
pathogen; the cost of which has limited its widespread
use particularly when related to the overall low inci-
dence of these conditions [4]. Multiplex arrays could be
a feasible alternative thanks to their high-throughput
performance and efficiency in terms of time and cost as
well as sample volume requirement.
We developed Luminex-based singleplex and multi-
plex microsphere Suspension Immuno Assays (SIAs) to
detect IgG antibodies against these three pathogens.
We determined the performances of the SIAs in se-
lected cohort groups (both in singleplex and multiplex
format) in comparison to corresponding high-quality in-
house or commercial EIAs.
Methods
The B19V IgG SIA was set up and examined at the
University of Helsinki while the CMV and T. gondii IgG
SIAs were set up at the Uppsala University Hospital.
The multiplex IgG SIA for the three pathogens was per-
formed at the University of Helsinki.* Correspondence: yilin.wang@helsinki.fi
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Study populations
B19V IgG SIA: serum samples from 80 children or
adults (2 to 58 years of age, median 10 years) with symp-
tomatic B19V infection [1, 5]. These included single
samples from 16 subjects and 171 samples from 64 sub-
jects followed up serologically for up to 700 days after
primary infection. As control group we included serum
samples from 104 constitutionally healthy medical stu-
dents. The seroprevalences of B19V and several emer-
ging viruses [6–8] have been previously determined with
these samples.
CMV and T. gondii IgG SIAs: serum samples from 72
subjects; single sera from 64 subjects and two consecu-
tive sera from eight subjects. These samples have been
tested for IgGs against T. gondii and CMV by the corre-
sponding Vidas enzyme linked fluorescent assays
(ELFAs, bioMérieux) and in-house B19V EIA.
For multiplex IgG SIA we used a total of 80 samples
as defined above in CMV and T. gondii IgG SIAs.
Coupling of antigens to magnetic/non-magnetic
microspheres
The following antigens were coupled with micro-
spheres: for B19V IgG, cloned and purified in-house re-
combinant VP2 virus-like particles (VLPs) [1, 5, 9]. For
CMV IgG, we used purified viral lysate (strain AD 169;
Advanced Biotechnology) and for T. gondii IgG, puri-
fied tachyzoite lysate (RH strain; Advanced Biotechnol-
ogy). The antigens and conditions for each assay are
presented in Table 1.
The B19V-magnetic microsphere coupling was per-
formed according to manufacturer’s protocol (“Sample
protocol for two step carbodiimide coupling of protein
to magnetic microsphere”, Luminex based xMap technol-
ogy). In each coupling, a total of 1.25 × 106 microsphere
(100 μl) were coated with the corresponding antigen/pro-
tein followed by blocking with PBS + 50 mM/L Tris +
0.5 mL/L Tween-20 [10]. The coupled microspheres were
washed twice with StabilGuard buffer (SG, SurModics)
and stored in 1 mL SG at 4 °C in the dark. The antigen
concentration was optimized by titration ranging from 200
ug to 0.8 ug per coupling.
The CMV- and T. gondii- microsphere couplings were
performed using non-magnetic microspheres as de-
scribed by Elfaitouri et al. [11].
Internal controls
Naked microspheres
To estimate nonspecific binding, each test sample was
run together with uncoupled (“naked”) microspheres
stored in SG.
Suspension immunoassays
The B19V SIA was performed following the manufac-
turer’s protocol (“Sample protocol for indirect antibody
capture immunoassay”). The B19V SIA was optimized
with serial serum dilutions ranging from 1:5 to 1:320 in
phosphate buffered saline with 0.05 % Tween-20 (PBST).
The optimal serum dilution is presented in Table 1.
Naked microspheres were included as background con-
trol. In brief, 50 μl of diluted sera were dispersed in each
well of 96-well flat bottom plate. Then the diluted sera
were incubated with B19V-coated and naked micro-
spheres for 45 minutes in the dark. After 3 times wash-
ing cycles, 50 μl of 2 ~ 4 μg/ml biotinylated protein G
(Thermo Scientific) was added in each well. The plate
was thoroughly mixed and incubated for 30 minutes in
the dark. After 3 times washing cycles, the specific signal
was developed by incubation with 2 ~ 4 μg/ml streptavi-
din conjugated phycoerythrin (R-PE, Life Technologies)
in PBST. Each well was resuspended in 120 μl of PBST
and read on the Bio-Plex®200 instrument.
The CMV and T. gondii SIAs were performed as de-
scribed [11]. They were also compared with 27 sera
against the corresponding Siemens BEPIII IgG tests, with
good concordance (courtesy of Bo Albinson, Uppsala; data
not shown).
Multiplex IgG SIA
We tested the B19V, CMV and T. gondii IgG SIAs in the
multiplex format using 80 sera with known IgG reactiv-
ity, and in the same assay conditions as specified for the
B19V IgG SIA.
Table 1 Antigens and conditions used in each assay
SIAs Antigen (Ag) Ag amount(/coupling) Serumdilution Cutoffcriterion Cutoff
B19V VP2 IgG Recombinant VP2 50 μg 1:20 Mean + 4 SD Negative < 453 MFIa
Mean + 5 SD Positive > 532 MFIa
CMV IgG Purified virion lysate 20 μg 1:20 Mean + 4 SD Negative < 695 MFIa
Mean + 5 SD Positive > 834 MFIa
T. gondii IgG Purified lysate 50 μg 1:20 Mean + 4 SD Negative < 234 MFIa
Positive > 234 MFIa
aMFI, median fluorescence intensity
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Reproducibility
In multiplex and singleplex SIAs, the intra-assay vari-
ability was calculated with 8 replicates in the same run,
and the inter-assay variability with 6 distinct runs.
Cutoff value determination
The SIAs cutoffs were calculated by the means and
standard deviations (SDs) of test values. For B19V IgG
SIA, the cutoff was defined with 72 sera confirmed to
be B19V seronegative by both Biotrin’s and in-house
B19V IgG and IgM EIAs. The sera were from children
with expiratory wheezing, studied earlier for human
bocavirus 1 [7]. The CMV and T. gondii cut-offs were
established with separate sets of 60 sera each. These
samples were IgG seronegative as confirmed by the
Abott assays (Table 1).
Statistical analysis
We used two-way contingency table analysis in ‘Vassar-
Stats’ for the calculation of kappa value, sensitivity, and
specificity. Borderline values in reference assays were ex-
cluded from the calculations. The agreement between
SIA and EIA was evaluated by kappa values and defined
as: poor (<0.20), fair (0.21–0.40), moderate (0.41–0.60),
good (0.61–0.80), and very good (0.81–1.00) [12]. Pear-
son correlation coeffients (R2) were calculated by Graph-
Pad Prism 6 to determine the correlation of results
between singleplex and multiplex IgG SIAs.
Cost calculation
The net cost was calculated by the sum of all the re-
agents’ costs (see Additional File 1).
Ethical approval
The Helsinki University Hospital Ethics Committee ap-
proved the use of all clinical samples included in this
study (Dnro 553/E6/2001, § 66, 13.4.2011). The control
serum samples in B19V SIA study were obtained from
the medical students with informed consent. All other
samples in this study were taken as part of standard care
and were analyzed anonymously.
Results
B19V IgG SIA
We validated the B19V IgG SIA using samples from a)
symptomatic B19V patients and b) constitutionally
healthy medical students.
From the symptomatic B19V individuals we tested 143
serum samples of which 16 corresponded to single sera
from 16 subjects and 127 follow-up sera from 49 sub-
jects. We found that 90 % (129/143) of the samples were
IgG positive and 4 had borderline results. All samples
collected >10 days after onset of symptoms showed a
100 % assay concordance with B19V IgG in-house EIA
(Fig. 1). The four borderline samples had been collected
within 6 days of onset; three of them were weakly posi-
tive in EIA (absorbance value: 0.2–0.4), and one was
negative. Overall, two discrepancies were found: one,
SIA+ EIA-, was collected on day 4 and the other, SIA-
EIA+, on day 1 after onset (Fig. 2).
In the cohort of healthy individuals, we found a sero-
positivity of 60 % in B19V IgG SIA. This finding was in
full agreement with that of EIA (Fig. 2).
Compared to in-house EIA, the B19V IgG SIA showed
98 % in both sensitivity and specificity, with very good
agreement (kappa coefficient 95 %; CI: 0.95 ~ 1). The
intra-assay and inter-assay variability of B19V IgG SIA
were 3 ~ 8 % and 1 ~ 12 %.
CMV and T. gondii IgG SIAs
We used samples with known reactivity against CMV
and T. gondii in commercial assays. In concordance with
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Fig. 1 IgG response to B19V VP2. Represented are the IgG seroresponses to B19V VP2 (circle in blue) in 65 subjects with symptomatic B19V
infection. The controls were asymptomatic individuals of whom 63 were IgG positive by B19V VP2 (box dot in green). Shown with diamond are
the IgG seronegative healthy individuals from the same control cohort. Y-axis shows median fluorescence intensity (MFI) by SIA and x-axis shows
days after onset. The vertical dashed line represents day 0 after onset of symptoms. The horizontal dashed lines depict the B19V IgG SIA
cutoff values
Wang et al. BMC Infectious Diseases  (2016) 16:8 Page 3 of 6
both CMV and T. gondii IgG Vidas ELFAs, we found
that 75 % (59/79) of the samples were positive in the
CMV IgG SIA while 60 % (46/77) were positive in the
T. gondii IgG SIA (Fig. 3).
Compared to Vidas ELFAs, the multiplex CMV and
T. gondii IgG SIAs showed 100 % sensitivity and speci-
ficity; with very good agreement (kappa coefficient with
95 %; CI: 1).
The intra-assay and inter-assay variability of CMV IgG
SIA were 3 ~ 7 % and 4 ~ 9 %, and those of T. gondii IgG
SIA were 7 ~ 12 % and 8 ~ 15 %, respectively.
Multiplex IgG SIA
We tested the B19V, CMV and T. gondii IgG SIAs with
80 sera of known IgG reactivity in the multiplex for-
mat. Pearson correlation coeffients (R2) in Fig. 4 shows
good correlation between multiplex and singleplex SIA.
The B19V IgG seropositivity corresponded well with
those obtained with EIA except for a single discrepancy
(SIA+, EIA-). The CMV and T. gondii IgG seropositiv-
ity corresponded perfectly with those obtained with
Vidas ELFA, though the assay condition as specified
for the B19V IgG SIA. The good performance of the
multiplex IgG SIA indicated no interference among the
three IgG SIAs (Fig. 4).
The intra-assay and inter-assay variability of multiplex
B19V IgG SIA were 2 ~ 8 % and 1 ~ 9 %, of multiplex
CMV IgG SIA were 4 ~ 8 % and 5 ~ 13 %, of multiplex T.
gondii IgG SIA were 6 ~ 9 % and 8 ~ 12 %, respectively.
Discussion
We established and validated singleplex and multiplex
microsphere-based platforms for simultaneous detection
of IgG against B19V, T. gondii and CMV. The assays
were highly sensitive and specific, with no interference
observable. All assays had a wide dynamic range, albeit
with T. gondii lower than with B19V or CMV. The CMV
and T. gondii IgG SIAs performed well in the multiplex
format, using the same assay conditions as for the B19V
IgG SIA e.g. magnetic microspheres, indicating good
assay reproducibility.
The SIAs detected reliably the seroresponses against
these three pathogens with an estimated net cost per
sample of 0.2€ [13] for singleplex and 0.35€ for triplex,
making these tools beneficial financially. Moreover,
multiplex is superior to singleplex in terms of time,
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Fig. 2 Comparison of B19V IgG results by SIA and EIA. Represented
is the comparison of IgG levels determined by SIA (y-axis) and EIA
(x-axis) in sera from patients with symptomatic B19V-infection (circle
in blue). Circle dots in red show two discrepancies between SIA and
EIA. The controls were asymptomatic individuals of whom 63 were
IgG positive by B19V VP2 (box dot in green). Shown with diamond
are the IgG seronegative healthy individuals from the same control
cohort. The horizontal and vertical dashed lines depict the B19V IgG
SIA and EIA cutoff values, respectively
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Fig. 3 Comparison of anti-CMV and anti-T. gondii IgG seroresponses
by SIA and ELFA. Represented are (a) CMV IgG and (b) T. gondii IgG
responses by SIAs (y-axis) or Vidas ELFA (x-axis) from 72 individuals.
Horizontal dot lines indicate the cutoffs between negative and
positive samples
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sample volume, amount of reagents and hands-on time.
The multiplex- Luminex technology is flexible, and other
assays maybe included in the present panel.
It also allows the possibility of including internal con-
trols to individual samples thus providing a measure of
the reliability of each readout.
Our SIA results were highly concordant with those of
other immunoassays of various types (in-house EIA,
Biotrin’s EIA, Vidas ELFA). The few discrepancies noted,
occurred mostly in samples from early infection, possibly
due to low antibody affinity. Other explanations may lay
in the intrinsic differences between SIA and EIA-based
reference assays [14, 15]: such as (i) fluorescence vs. col-
orimetric substrate detection, (ii) antigen coupling cova-
lently onto magnetic microspheres vs. via adsorption
onto streptavidin-coated plates in our in house EIAs,
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Fig. 4 Comparison of anti-B19V, −CMV and -T. gondii IgG seroresponses by multiplex and singleplex SIAs/EIA. The left figures (a), (b) and (c)
represented B19, CMV and T. gondii IgG responses by multiplex SIAs (y-axis) and singleplex SIAs (x-axis), respectively. The right figures (d), (e) and
(f) represented B19V, CMV and T. gondii IgG responses by multiplex SIAs (y-axis) and the corresponding reference EIA/ELFA (x-axis), respectively.
Horizontal dot lines indicate the cutoffs between negative and positive samples
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(iii) antibody detection with protein G as opposed to
anti-human IgG.
Of note, during the development of these assays, we
found that post-coat blocking of the microsphere with
bovine serum albumin (BSA) yielded inappropriately
high background in some individuals (our unpublished
data). However, replacement of BSA with Tris signifi-
cantly improved the signal-to-noise ratios [10].
In this study, we used well-characterised cohorts of
sera and controls in our singleplex and multiplex SIAs
and we show good reproducibility in comparison to ref-
erence assays. However, as the test parameters were
calculated based on a limited number of samples, its
performance should be further validated with other clin-
ical cohorts. Moreover, other assays such as IgG-avidity
and IgM may aid in the diagnosis of acute infection and
are currently under development in our lab.
Conclusion
We showed that IgG antibodies against B19V, T. gondii
and CMV are successfully detected using the microsphere-
based suspension assay both in single and multiplex
formats, making it a powerful microbiological tool.
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